Keith Regnante, CHIEF FINANCIAL OFFICER at Keros Therapeutics, Inc. (KROS), sold 40,000 shares at $45.29 ($1.8M) on 2024-01-04, disclosed to the SEC on 2025-01-24.
Open-market sale of $1.8M KROS by CHIEF FINANCIAL OFFICER. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KROS | SELL | 2023-06-12 | $3.7M | — | Filing → |
| WVE | SELL | 2019-02-21 | $48K | — | Filing → |
| WVE | SELL | 2018-09-26 | $1.6M | — | Filing → |